Episode Details

Enlivex CEO Oren Hershlovitz joined Steve Darling from Proactive to discuss the company’s dual strategy of advancing late-stage clinical drug development while building a digital asset treasury initiative tied to decentralized prediction markets. Hershkovitz explained that Enlivex continues progressing development of Allocetra for osteoarthritis while simultaneously gaining exposure to the growing prediction market sector through the RAIN token ecosystem. The company completed a transformative transaction at the end of 2025 that established a treasury strategy centered around the RAIN protocol, which management describes as a decentralized prediction market platform. Enlivex invested more than $200 million in RAIN tokens and also secured an exclusive option to acquire additional tokens at a fixed price. Hershkovitz said the structure provides shareholders with significant upside exposure tied to the future growth of the protocol and broader adoption of decentralized prediction markets. On the clinical side, Enlivex continues advancing Allocetra™ for knee osteoarthritis. The company previously completed a Phase 2a double-blind, placebo-controlled study that demonstrated statistically significant improvements in pain reduction and functional outcomes among patients over the age of 64. Enlivex has now received authorization from the U.S. Food and Drug Administration to begin a Phase 2b study and has also secured Clinical Trial Application approval in Denmark. Topline results from the Phase 2b trial are expected in the first half of 2027 and could support advancement into Phase 3 development. The company believes its combination of biotechnology development and strategic exposure to emerging digital asset infrastructure creates a differentiated growth profile as both sectors continue to evolve. #proactiveinvestors #enlivixltd #nasdaq #enlv #Biotech #Allocetra #Osteoarthritis #ClinicalTrials #PredictionMarkets #DigitalAssets #RAINToken #HealthcareInnovation